Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal Zymeworks said on Friday Roche has gained rights to develop and commercialize its experimental lung cancer drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results